Abstracts tagged "Anti-TNF therapy and rheumatoid arthritis"

Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression
Ozge Kockara¹, Merve Sibel Gungoren², Erdem Karabulut³, Sebnem Ataman⁴ and Filiz Akbiyik², ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…
Abstract Number: 2783 • 2015 ACR/ARHP Annual Meeting
What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Edward C. Keystone¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Although the majority of RA patients respond to treatment with anti-TNF agents, some patients present with refractory disease (1ry failure) while others show some…
Abstract Number: 1559 • 2012 ACR/ARHP Annual Meeting
Treatment Outcomes From a Nurse-Led Rheumatology Clinic in Monitoring of anti-TNF Therapy – a Randomised Controlled Trial
Ingrid Larsson¹, Bengt Fridlund¹, Barbro Arvidsson², Annika Teleman³ and Stefan Bergman⁴, ¹Jönköping University, Jönköping, School of Health Sciences, Jönköping University, Jönköping, Sweden, ²Halmstad University, School of Social and Health Sciences, Halmstad University, Halmstad, Sweden, ³Spenshults Hosp of Rheum Dis, Oskarstrom, Sweden, ⁴Spenshult Hospital, R&D Center, Spenshult Hospital, Oskarström, Sweden
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) treated with anti-TNF therapy are usually followed up by rheumatologists. Nurse-led rheumatology clinics have been proposed for patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].